Progressive malignant disease is often associated with the syndrome of cachexia, characterised by loss of both adipose tissue and muscle to such an extent that death appears to occur by starvation (Inagaki et al., 1974) . However, numerous studies on the abnormalities in host metabolism indicate that cancer cachexia is not the same as simple starvation (Brennan, 1977) and clinically the predominant feature distinguishing cancer cachexia from malnutrition in a nonneoplastic condition is the absence of response to aggressive nutritional support (Chlebowski, 1985; Wesdorp et al., 1983) . While anorexia is invariably present in most cancer patients this may not be manifested until weight loss is established (De Wys et al., 1981) and the metabolic effects of the tumour may be more important in the initiation and maintenance of the cachectic condition.
Several mediators have been proposed to be responsible for the cachectic condition, but unfortunately most studies do not distinguish between the cachexia which occurs in cancer, with that in chronic infectious conditions. Thus cachectin/tumour necrosis factor (TNF) was originally isolated as the mediator of the biochemical changes in the cachexia in rabbits infected with Trypanosoma brucei (Kawakami & Cerami, 1981) , although the range of cachexia was soon extended to include cancer cachexia (Beutler & Cerami, 1986) . While TNF is capable of inducing weight loss in animals, either by direct injection (Mahony et al., 1988) or by implantation of tumour cells transfected with the cachectin/TNF gene (Oliff et al., 1987) , the data to support a role for TNF in all human cachexias is less convincing. Thus, while elevated levels of circulating TNF have been detected in patients withm the acquired immunodeficiency syndrome (AIDS) (Lahdevirta et al., 1988) , kala-azar (visceral leishmaniasis) and malaria (Scuderi et al., 1986) (Selby et al., 1987; Socher et al., 1988) . These results suggest that there may be other mediators of the cachexia in cancer patients.
We have utilised a murine colon adenocarcinoma (MAC16) to study the metabolic effects of the tumour on the host. At a body burden of only 2% this tumour produces a 33% reduction in host body weight, without a reduction in food or water intake (Bibby et al., 1987) . Cachexia in animals transplanted with the MAC16 tumours is associated with the presence of circulatory catabolic factors capable of breaking down both muscle and adipose tissue in vitro (Beck & Tisdale, 1987) . Similar elevations in lipid mobilising activity have recently been found in the serum and urine of patients with clinical cancer cachexia (Groundwater et al., 1990 ) and this study attempts to further characterise this activity.
Materials and methods
Pure strain NMRI mice were bred in our own colony. They were fed a rat and mouse breeding diet (Pilsbury, Birmingham, UK) and water ad libitum. Male mice (weight 26 to 28 g) were transplanted in the flank with fragments of the solid MAC16 tumour as previously described (Kitada et al., 1981) . Tumours were removed from animals with established weight loss and homogenised (10% w/v) at 4'C in KrebsRinger bicarbonate buffer, pH 7.6, and centrifuged for 10 min at 3,000 g to remove debris. Human colon carcinomas were obtained from the operating theatre of Dudley Road Hospital, Birmingham, UK (courtesy of Mr J. Neoptolemos) and were homogenised under the same conditions. The tumour supernatants were used for further characterisation.
Effect of starvation on lipolytic activity
Male NMRI mice (10 to 12 weeks old) were starved for 24 h in metabolic cages. Water was provided ad libitum. Urine was collected for further analysis and body composition analysis was determined by the method of Lundholm et al. (1980) as previously described (Beck & Tisdale, 1987) . Blood was removed from animals, using a heparinised syringe, by cardiac puncture, under anaesthesia with a mixture of halothane, oxygen and nitrous oxide. Glucose levels were determined on whole blood with the use of the o-toluidine reagent kit (Sigma Diagnostics, Poole, Dorset, UK). Plasma was prepared by centrifuging whole blood for 30 s and free fatty acid (FFA) levels were determined using a Walko NEFA C kit (Alpha Laboratories Ltd, Hampshire, UK). Urine creatinine concnetration was determined colourimetrically at 500 nm using a reagent kit (Sigma Diagnostics, Poole, Dorset, UK).
Six human control subjects volunteered to starve for 24 h, during which time only water intake was allowed. Urine and blood samples were provided, both prior to and after starvation, and were assayed for the presence of lipolytic activity.
Exclusion chromatography Both mouse and human urine were fractionated using a Sephadex G50 column (1.6 x 30 cm) equilibrated with 10 mM phosphate, pH 8.0, and eluted at a flow rate of 15 ml h'. The void volume of the column (17 ml) was determined by blue dextran. The effluent from the column was collected in 1 ml fractions and the lipolytic activity of 0.5 ml samples was determined as described below. The column was calibrated with standards (cytochrome c, aprotinin, actinomycin D and rifampicin) of known molecular weight. 
Results
Despite the fact that animals bearing the MAC16 tumour have a food and water intake not significantly different from non tumour-bearing controls, weight loss is observed, which increases as the tumour burden increases (Table I) . We have attempted to compare the situation with starvation for 24 h where a similar weight loss is attained (Table I ). The plasma levels of both glucose and FFA were reduced to a similar extent in both situations and body composition analysis showed a similar reduction in carcass fat, although the reduction in muscle dry weight, as measured by the thigh plus gastrocnemius muscles, was slightly less in the starved than in the cachetic animals.
The lipolytic activity of body fluids has been measured by the ability to liberate glycerol from freshly prepared murine epididymal adipocytes. Previous studies (Beck & Tisdale, 1987) have employed measurement of FFA release and substantially similar results are obtained with the two methods. The results in Table II show that both urine and plasma of A similar situation was observed in a patient with clinical cancer cachexia, who also displayed an elevated plasma and urinary lipolytic activity compared with the normal controls (Table II) . Again starvation significantly increased the plasma lipolytic activity of normal subjects, although the value was still significantly less than in the cachectic patient, but had not effect on the urinary lipolytic activity.
In order to investigate the molecular species responsible for the enhanced lipolytic activity of cachectic mouse urine an aliquot of urine from a mouse bearing the MAC 16 tumour was subjected to exclusion chromatography using Sephadex G50. The lipolytic activity was mainly eluted at the void volume of the column, but was accompanied by three smaller peaks of activity with apparent molecular weights of 3, 1.5 and <0.7 kDa (Figure la) . No comparable peaks of lipolytic activity were observed in the urine from a non tumourbearing mouse (Figure lc) . The material eluting at the void volume of the column appeared to be an aggregate of the low molecular weight material, since treatment with 0.5 M NaCl and rechromatography on Sephadex G50 gave a broad range of activity peaks eluting between apparent molecular weights of 3 and 0.7 kDa, with no material eluting at the void volume (Figure lb) . Similar lipolytic species with apparent molecular weights similar to that found in mouse urine were also observed in the urine of a cachectic cancer patient, when subjected to Sephadex G50 chromatography (Figure 2a ). Urine from control human subjects displayed no corresponding peaks of lipolytic activity, even after starvation for 24 h (Figure 2b ).
These results suggest that the elevated lypolytic activity in the urine of animals bearing the MAC16 tumour and in patients with cancer cachexia is due to distinct molecular species.
Samples of fresh human colon adenocarcinomas, and in two cases the corresponding non-involved colonic tissue, were homogenised and assayed for lipid mobilising acitivity, without initially having the patient characteristics. Out of five samples assayed, only one (patient 2, Table III) was subsequently found to have lost weight, and the lipid mobilising activity of this tumour was twice that of the corresponding tumours from patients without weight loss. For those patients where the non-involved colonic tissue was also available, the lipolytic activity of the tumour extracts was significantly higher than normal tissue, even though no weight loss was observed.
Discussion
Growth of the MAC16 tumour is associated with a progressive decrease in carcass lipids, although the animals consume normal amounts of food (Beck & Tisdale, 1987) . Studies in rats have shown that the decrease in body fat cannot be accounted for by a decreased caloric intake, since pair-fed animals did not lose as much fat as tumour-bearing animals (Lundholm et al., 1981) . This suggests the involvement of a lipid mobilising factor in the catabolism of host adipose tissue in the cachectic state.
We have attempted to distinguish lipolysis in the cancer cachectic state from that occurring during starvation. Both states are associated with an increased plasma lipolytic activity, although the magnitude of the increase is higher in the cachectic state. Although a fat mobilising substance has been detected in the urine of man and some other mammals (Costa & Holland, 1962) . Later studies reported a lipid mobilising factor present in both the serum of mice bearing a thymic lymphoma and a patient with advanced cancer (Kitada et al., 1981) . The molecular weight of the material initially reported was 5 kDa, similar to that described in the present report, although later studies (Kitada et al., 1982) Figure 2 a, Sephadex G50 chromatography of a concentrated sample (100 ml) of urine from a male patient with teratoma and a total weight loss of 6.3 kg at the time urine was collected. b, Sephadex G50 chromatography of a sample (128 ml) of urine combined from control subjects after 24 h of starvation. Lipolytic activity is expressed as described in Methods.
to produce anorexia when injected into mice (Masuno et al., 1981) .
We have now shown that urine of both mice and humans with cancer cachexia appears to contain distinct molecular species with lipid mobilising activity which are absent during starvation. The true lipid mobilising fractions are probably of low molecular weight since the high molecular weight material is capable of being dissociated to the lower molecular weight forms with salt, suggesting an aggregation or non specific attachment to urinary proteins. We have recently shown (Groundwater et al., 1990 ) that patients with cancer cachexia have increased levels of both serum and urinary lipid mobilising activity which increases with increasing weight loss up to a maximum body weight loss of 16-20%. Higher levels of lipolytic activity are also present in a tumour extract from a patient with an adenocarcinoma of the colon with established weight loss, than from tumours from patients without weight loss, although preliminary data suggests that the lipolytic activity of the other tumours is higher than the normal colonic mucosa. Similar results were obtained in the MAC series of murine colon adenocarcinomas (Beck & Tisdale, 1987) where, although the cachexia-inducing MAC16 tumour had the highest lipolytic activity, significant activity was also found in the other tumour types. This suggests that tumours may have a system for obtaining lipids from the host, which may be utilised when de novo biosynthesis is insufficient to meet the metabolic demands. Tumours obtain a substantial amount of preformed fatty acid from the host (Spector, 1975) either as circulating FFA (Mermier & Baker, 1974) or to a lesser extent from the triacylglycerols contained in plasma lipoproteins (Brenneman & Spector, 1974) , despite the fact that tumours can synthesise fatty acids from glucose (Kannan et al., 1980) . Conditions which stimulate mobilisation of fatty acids from adipose tissue such as diabetes mellitus (Sauer & Dauchy, 1987a) and acute fasting (Sauer & Dauchy, 1987b ) also stimulate the growth of the tumour. These findings suggest that the availability of nutrients derived from host fat stores may be rate limiting for tumour growth in vivo, which could provide some logic for the production by tumour cells of a substance capable, through some sort of receptor interaction, of mobilising lipids from host fat stores.
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